Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MURA 
Mural Oncology plc (MURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MURA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.86% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.86M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 0.95 - 4.74 | Updated Date 09/16/2025 |
52 Weeks Range 0.95 - 4.74 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.6% | Return on Equity (TTM) -111.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -35885477 | Price to Sales(TTM) - |
Enterprise Value -35885477 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 17324800 | Shares Floating 12281585 |
Shares Outstanding 17324800 | Shares Floating 12281585 | ||
Percent Insiders 13.03 | Percent Institutions 57.62 |
Upturn AI SWOT
Mural Oncology plc
Company Overview
History and Background
Mural Oncology plc, formerly known as Alkermes plc, rebranded after separating its neuroscience business. The company is focused on developing differentiated cell therapies for a range of cancers. Founding year for Alkermes was 1987. Mural Oncology's formation and new strategic focus occurred more recently, following the separation.
Core Business Areas
- Cell Therapies: Mural Oncology focuses on the development and commercialization of cell therapies targeting solid tumors. This includes novel cytokine therapies and related immuno-oncology approaches.
Leadership and Structure
Information not readily available in current databases. Needs to be updated as the company is a recent spinoff. This section would describe the executive team (CEO, CFO, etc.) and a high-level overview of the organizational hierarchy.
Top Products and Market Share
Key Offerings
- Nuvoretigene parek-vek: Formerly with Alkermes, Mural Oncology doesn't currently have products already on the market. They are focused on products in clinical trials. As such, there is no current market share or revenue associated with products developed specifically by Mural Oncology. Competitors vary by cancer type and therapy type (e.g., CAR-T therapies from Novartis and Gilead).
Market Dynamics
Industry Overview
The cell therapy market is a rapidly growing area within oncology, driven by advances in immunotherapy and genetic engineering. The market is highly competitive, with many companies developing novel therapies.
Positioning
Mural Oncology is positioned as a developer of novel cell therapies for solid tumors, aiming to address areas of unmet need. Specific competitive advantages would depend on the clinical trial outcomes of their pipeline products.
Total Addressable Market (TAM)
The TAM for cell therapies is projected to reach tens of billions of dollars in the coming years. Mural Oncology's position within this TAM depends on the success of their clinical programs and their ability to commercialize effective therapies.
Upturn SWOT Analysis
Strengths
- Focus on cell therapies for solid tumors
- Novel cytokine therapies platform
- Experienced management team from Alkermes
Weaknesses
- No currently marketed products
- Reliance on clinical trial success
- High development costs
Opportunities
- Growing cell therapy market
- Partnerships and collaborations
- Expansion into new cancer indications
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
- JNJ
Competitive Landscape
Mural Oncology faces intense competition from established pharmaceutical companies with greater resources and existing marketed products. Mural Oncology's advantage will lie in the novelty and efficacy of its cell therapy approaches.
Growth Trajectory and Initiatives
Historical Growth: No meaningful historical growth data available.
Future Projections: Future growth projections are highly dependent on the success of Mural Oncology's clinical trials and the subsequent commercialization of its therapies. Analyst estimates are not yet widely available.
Recent Initiatives: Focus on developing and advancing pipeline of novel cell therapies for solid tumors; pipeline programs in clinical trials.
Summary
Mural Oncology is a newly formed company focused on a promising area of oncology, cell therapy. However, its success hinges on the successful development and commercialization of its pipeline programs, which presents significant risk. The company will need to navigate a competitive landscape and secure adequate funding. Mural Oncology will need to show that it is competitive on pricing and efficacy against other competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Press Releases
- Company Website
- SEC Filings
- Third-Party Market Research Reports
Disclaimers:
This analysis is based on currently available information and is subject to change. It is not financial advice. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mural Oncology plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-11-16 | President, CEO & Director Ms. Caroline J. Loew Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | Website https://www.muraloncology.com |
Full time employees 116 | Website https://www.muraloncology.com | ||
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.